Current Developments in Targeted Drug Delivery Systems for Glioma

Area of Science:

• Neuro-oncology
• Nanomedicine
• Biotechnology

Background:

• Glioma accounts for 75% of adult brain tumors, with current treatments like surgery, radiotherapy, and chemotherapy yielding unsatisfactory outcomes.
• Existing chemotherapy drugs face challenges due to the blood-brain barrier, leading to recurrence, and lack of target specificity, affecting healthy cells.
• Effective glioma treatment necessitates targeted drug delivery to improve efficacy and reduce recurrence rates.

Purpose of the Study:

• To review current glioma treatment challenges and explore advancements in targeted drug delivery strategies.
• To provide insights into factors influencing drug delivery within the brain for glioma patients.
• To highlight recent developments in overcoming therapeutic barriers for brain tumors.

Main Methods:

• A comprehensive literature search was performed using major scientific databases (PubMed, Web of Science, Scopus, Google Scholar).
• The search focused on glioma pathophysiology, current therapeutic strategies, and targeted drug delivery approaches.
• Information was synthesized to analyze challenges and recent advancements in the field.

Main Results:

• Current glioma therapies often fail due to the blood-brain barrier and non-specific drug action.
• Nanotechnology-based approaches, including polymeric, lipid-based, and hybrid nanoparticles, demonstrate significant potential.
• Biotechnological advancements like carrier peptides and gene therapy represent promising future directions.

Conclusions:

• Nanotechnology offers promising avenues for effective glioma treatment through targeted delivery systems.
• Biotechnological innovations are emerging as key future strategies for enhancing glioma therapy.
• Targeted delivery systems are poised to significantly benefit clinical practices in managing glioma.